Skip to main content

Table 1 Effect of ketone supplements on blood βHB and glucose levels on the 7th day of gavage

From: Inhibition of adenosine A1 receptors abolished the nutritional ketosis-evoked delay in the onset of isoflurane-induced anesthesia in Wistar Albino Glaxo Rijswijk rats

 

Blood βHB level

Treatments (2.5 g/kg/day; Fig. 1a)

Baseline

7th treatment day

mmol/l (mean ± S.E.M.)

mmol/l (mean ± S.E.M.)

Compared to baseline (significance level/q-value)

Compared to control (significance level/q-value)

SD (control; group 1)

0.80 ± 0.037

0.86 ± 0.018

−/0.945

–

KE (group 2)

0.79 ± 0.029

1.76 ± 0.087

****/14.550

****/13.610

KS (group 3)

0.83 ± 0.031

1.25 ± 0.033

***/6.805

**/5.860

KSMCT (group 4)

0.81 ± 0.023

1.33 ± 0.049

****/7.939

***/6.994

KEKS (group 5)

0.83 ± 0.041

1.55 ± 0.073

****/11.340

****/10.400

KEMCT (group 6)

0.80 ± 0.033

2.14 ± 0.172

****/20.230

****/19.280

 

Blood glucose level

Treatments (2.5 g/kg/day; Fig. 1b)

Baseline

7th treatment day

mg/dl (mean ± S.E.M.)

mg/dl (mean ± S.E.M.)

Compared to baseline (significance level/q-value)

Compared to control (significance level/q-value)

SD (control; group 1)

89.00 ± 1.937

95.38 ± 2.672

−/1.764

–

KE (group 2)

91.50 ± 2.284

97.63 ± 4.342

−/2.386

−/0.623

KS (group 3)

88.38 ± 1.772

100.13 ± 5.482

−/3.078

−/1.314

KSMCT (group 4)

83.63 ± 3.600

97.00 ± 5.745

−/2.213

−/0.449

KEKS (group 5)

86.38 ± 2.398

92.13 ± 3.388

−/0.865

−/0.899

KEMCT (group 6)

85.00 ± 2.659

80.88 ± 4.286

−/2.248

−/4.011

  1. Abbreviations: KE, ketone ester; KEKS, mix of KE and KS in a 1:1 ratio; KEMCT, mix of KE and medium chain triglyceride (MCT) oil in a 1:1 ratio; KS, ketone salt; KSMCT, mix of KS and MCT oil in a 1:1 ratio; SD, standard diet/control; **p < 0.01; ***p < 0.001; ****p < 0.0001